

## Type XVI RTKs: DDR (collagen receptor) family in GtoPdb v.2025.3

Birgit Leitinger<sup>1</sup> and Chloe J. Peach<sup>2</sup>

1. Imperial College London, UK
2. University of Nottingham, UK

### Abstract

The discoidin domain receptors DDR1 and DDR2 are structurally related receptor tyrosine kinases that function as collagen receptors. The 28 different collagens form the most abundant protein family in man. Collagens are found in the extracellular matrix and are generally deposited there in the form of supramolecular assemblies arranged from triple-helical rope-like structural units. In man, the main collagens include [COL1A1](#), [COL2A1](#), [COL3A1](#) and [COL4A1](#).

### Contents

This is a citation summary for Type XVI RTKs: DDR (collagen receptor) family in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [3].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

### Database links

#### Type XVI RTKs: DDR (collagen receptor) family

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=331>

#### Receptors

##### [DDR1 \(discoidin domain receptor tyrosine kinase 1\)](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1843>

##### [DDR2 \(discoidin domain receptor tyrosine kinase 2\)](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1844>

### References

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H and Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1039-45 [[PMID:22037377](#)]
2. Borza CM and Pozzi A. (2014) Discoidin domain receptors in disease. *Matrix Biol* **34**: 185-92 [[PMID:24361528](#)]
3. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [[PMID:32367113](#)]
4. Carafoli F, Bihan D, Stathopoulos S, Konitsiotis AD, Kvensakul M, Farndale RW, Leitinger B and

- Hohenester E. (2009) Crystallographic insight into collagen recognition by discoidin domain receptor 2. *Structure* **17**: 1573-81 [PMID:20004161]
5. Carafoli F, Mayer MC, Shiraishi K, Pecheva MA, Chan LY, Nan R, Leitinger B and Hohenester E. (2012) Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling. *Structure* **20**: 688-97 [PMID:22483115]
  6. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1046-51 [PMID:22037378]
  7. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C and Jarai G. (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. *Eur J Pharmacol* **599**: 44-53 [PMID:18938156]
  8. Gao M, Duan L, Luo J, Zhang L, Lu X, Zhang Y, Zhang Z, Tu Z, Xu Y and Ren X *et al.*. (2013) Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. *J Med Chem* **56**: 3281-95 [PMID:23521020]
  9. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R and Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. *Biochem J* **451**: 313-28 [PMID:23398362]
  10. Hart AC, Abell L, Guo J, Mertzman ME, Padmanabha R, Macor JE, Chaudhry C, Lu H, O'Malley K and Shaw PJ *et al.*. (2019) Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage *ACS Med Chem Lett*
  11. Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z and Wang J *et al.*. (2013) Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. *ACS Chem Biol* **8**: 2145-50 [PMID:23899692]
  12. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K and Kirii Y. (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. *Genes Cells* **18**: 110-22 [PMID:23279183]
  13. Leitinger B. (2014) Discoidin domain receptor functions in physiological and pathological conditions. *Int Rev Cell Mol Biol* **310**: 39-87 [PMID:24725424]
  14. Li Y, Lu X, Ren X and Ding K. (2015) Small molecule discoidin domain receptor kinase inhibitors and potential medical applications. *J Med Chem* **58**: 3287-301 [PMID:25569119]
  15. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z and Lin G *et al.*. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. *J Med Chem* **61**: 11398-11414 [PMID:30480444]
  16. Liu J, Chiang HC, Xiong W, Laurent V, Griffiths SC, Dülfer J, Deng H, Sun X, Yin YW and Li W *et al.*. (2023) A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer. *J Immunother Cancer* **11** [PMID:37328286]
  17. Murray CW, Berdini V, Buck IM, Carr ME, Cleasby A, Coyle JE, Curry JE, Day JE, Day PJ and Hearn K *et al.*. (2015) Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. *ACS Med Chem Lett* **6**: 798-803 [PMID:26191369]
  18. Patwardhan PP, Ivy KS, Musi E, de Stanchina E and Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. *Oncotarget* **7**: 4093-109 [PMID:26675259]
  19. Ramurthy S, Taft BR, Aversa RJ, Barsanti PA, Burger MT, Lou Y, Nishiguchi GA, Rico A, Setti L and Smith A *et al.*. (2020) Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. *J Med Chem* **63**: 2013-2027 [PMID:31059256]
  20. Wang Z, Bian H, Bartual SG, Du W, Luo J, Zhao H, Zhang S, Mo C, Zhou Y and Xu Y *et al.*. (2016) Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. *J Med Chem* **59**: 5911-6 [PMID:27219676]
  21. Wang Z, Zhang Y, Pinkas DM, Fox AE, Luo J, Huang H, Cui S, Xiang Q, Xu T and Xun Q *et al.*. (2018) Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. *J Med Chem* **61**: 7977-7990 [PMID:30075624]
  22. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC and Zarrinkar PP *et al.*. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. *Chem Biol* **17**: 1241-9 [PMID:21095574]
  23. Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z, Liu F, Liu Q, Chen C and Hu C *et al.*. (2019) Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. *J Med Chem* **62**: 6083-6101 [PMID:31250638]

24. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW and Manro JR *et al.*. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. *Invest New Drugs* **31**: 833-44 [[PMID:23275061](#)]
25. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD and Asadulaev A *et al.*. (2019) Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol* **37**: 1038-1040 [[PMID:31477924](#)]